Dr Reddy’s Partners with China’s Bio-Thera to Launch Stelara, Simponi Biosimilars in Southeast Asia

Rapid Summary

• Dr Reddy’s subsidiary has signed commercialisation and licensing agreements wiht China’s Bio-thera Solutions for biosimilars of Janssen’s monoclonal antibodies – stelara (BAT2206) and Simponi (BAT2506).
• The deal covers Southeast Asian markets, including Cambodia, Indonesia, Malaysia, Philippines, Thailand, and Vietnam.It also grants exclusive commercial rights to market BAT2206 in Colombia.
• Bio-Thera will develop, manufacture and supply the biosimilars; Dr Reddy’s will handle regulatory approvals and marketing in licensed territories.
• Stelara treats conditions like plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis by targeting IL-12/IL-23 responses; Simponi addresses rheumatoid arthritis and other inflammatory diseases by inhibiting TNF-alpha activity.
• Both companies’ ceos expressed optimism about expanding access to affordable medicines in emerging markets through this collaboration.

!Dr Reddy’s inks South East Asia commercialisation licence pacts with China’s Bio-Thera for Stelara Simponi biosimilars

Indian Opinion Analysis
Dr reddy’s newest partnership reflects India’s growing focus on addressing unmet medical needs through strategic collaborations in emerging markets. By aligning with bio-Thera Solutions for biosimilar development of Janssen drugs like stelara and Simponi-used extensively for managing autoimmune diseases-this agreement targets both affordability concerns and expanding market reach within Southeast Asia.

This move underscores India’s role as a key player in global pharmaceutical value chains by tapping into underserved regions where advanced therapeutics are frequently enough cost-prohibitive or unavailable. Regulatory clearance will be crucial to unlocking potential benefits from this partnership while providing enhanced access to innovative treatments across licensed territories-a notable step toward broader global healthcare equity grounded on affordability.

Read more